Dr. reddy's and rdif commence clinical trials for sputnik v vaccine in india

Hyderabad, india--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy), and russian direct investment fund (rdif) announced today that they have commenced adaptive phase 2/3 clinical trials for sputnik v vaccine in india after receiving the necessary clearance from the central drugs laboratory, kasauli, india. this will be a multicenter and randomized controlled study, which will include safety and immunogenicity study. the clinical trials are being conducted by
RDY Ratings Summary
RDY Quant Ranking